Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MMSI 
Merit Medical Systems Inc (MMSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MMSI (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 20.76% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.20B USD | Price to earnings Ratio 51.95 | 1Y Target Price 118.36 |
Price to earnings Ratio 51.95 | 1Y Target Price 118.36 | ||
Volume (30-day avg) 719428 | Beta 0.92 | 52 Weeks Range 70.70 - 111.45 | Updated Date 04/1/2025 |
52 Weeks Range 70.70 - 111.45 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.87% | Operating Margin (TTM) 11.21% |
Management Effectiveness
Return on Assets (TTM) 4.2% | Return on Equity (TTM) 9.33% |
Valuation
Trailing PE 51.95 | Forward PE 28.82 | Enterprise Value 6622055195 | Price to Sales(TTM) 4.57 |
Enterprise Value 6622055195 | Price to Sales(TTM) 4.57 | ||
Enterprise Value to Revenue 4.88 | Enterprise Value to EBITDA 22.38 | Shares Outstanding 58834600 | Shares Floating 57421362 |
Shares Outstanding 58834600 | Shares Floating 57421362 | ||
Percent Insiders 2.57 | Percent Institutions 105.92 |
Analyst Ratings
Rating 4.4 | Target Price 113.7 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Merit Medical Systems Inc
Company Overview
History and Background
Merit Medical Systems, Inc. was founded in 1987 by Fred P. Lampropoulos. It is a publicly traded company focused on designing, developing, manufacturing, and distributing proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy.
Core Business Areas
- Cardiovascular: Merit's cardiovascular segment focuses on products used in interventional cardiology and cardiac rhythm management procedures, including diagnostic and therapeutic catheters, inflation devices, and hemostasis products.
- Endoscopy: The endoscopy segment offers products for various endoscopic procedures, including biopsy forceps, snares, and other devices used in gastroenterology and pulmonology.
- Interventional Oncology and Critical Care: This segment focuses on devices for treating tumors and providing critical care access, including microcatheters, embolization products, and central venous catheters.
- Peripheral Intervention: This segment includes devices used in diagnostic and therapeutic procedures to treat vascular conditions, including PTA balloons and stents.
Leadership and Structure
Fred P. Lampropoulos serves as the Chairman and Chief Executive Officer. The company has a typical corporate structure with various departments including R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Embosphere Microspheres: Used for embolization procedures to treat tumors. Competitors include Boston Scientific and Cook Medical. Market share data specific to this product is not publicly available but this remains a key product for Merit. TAM for embolic agents is estimated at $1.5 Billion.
- Concerto ONYX Detachable Balloon: Used in interventional procedures. Competitors include Medtronic and Stryker. Revenue from this product is not specified. Used in neurovascular procedures.
- HeRO Graft: A fully subcutaneous hemodialysis access graft. Competitors include W.L. Gore and BD(Becton, Dickinson and Company). Revenue data specifically for HeRO Graft is not specified, but is important for their renal market.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory scrutiny, and intense competition. Trends include minimally invasive procedures, technological advancements, and increasing demand for healthcare services due to aging populations.
Positioning
Merit Medical occupies a niche in the interventional medical device market, focusing on specialized disposable products. Their competitive advantages include a broad product portfolio, strong distribution network, and focus on innovation.
Total Addressable Market (TAM)
The total addressable market for Merit Medical's product categories is estimated to be in the billions of dollars, encompassing various interventional and diagnostic procedures. Merit is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Broad Product Portfolio
- Strong Distribution Network
- Focus on Innovation
- Experienced Management Team
- Strong Brand Reputation within target medical specialties
Weaknesses
- Reliance on Key Products
- Exposure to Regulatory Changes
- Dependence on Third-Party Suppliers
- Smaller Scale Compared to Larger Competitors
- High Debt levels
Opportunities
- Expanding into New Geographies
- Developing New Products and Technologies
- Acquiring Complementary Businesses
- Growing Demand for Minimally Invasive Procedures
- Increasing Aging Population globally
Threats
- Intense Competition
- Pricing Pressures
- Product Liability Claims
- Economic Downturns
- Supply chain disruption
Competitors and Market Share
Key Competitors
- BSX
- MDTC
- COOK MEDICAL INC
Competitive Landscape
Merit Medical faces competition from larger, more diversified medical device companies. However, Merit's focus on specialized products and strong relationships with physicians provide a competitive edge.
Major Acquisitions
Cianna Medical, Inc.
- Year: 2019
- Acquisition Price (USD millions): 200
- Strategic Rationale: Expanded Merit's portfolio in breast cancer localization and surgical guidance.
Vascular Insights, LLC
- Year: 2023
- Acquisition Price (USD millions): 70
- Strategic Rationale: Added complementary technologies in the treatment of venous disease.
Growth Trajectory and Initiatives
Historical Growth: Merit Medical has historically grown through organic product development and strategic acquisitions.
Future Projections: Analyst estimates project continued revenue growth and profitability improvements for Merit Medical. These should be examined as part of regular company research.
Recent Initiatives: Recent strategic initiatives include expanding into new markets, launching new products, and streamlining operations.
Summary
Merit Medical Systems is a mid-sized player in the interventional medical device market with a diversified product portfolio and a history of growth through acquisition and product development. The company benefits from its strong distribution network and focus on specialized products, but also faces competition from larger players and regulatory hurdles. While Merit Medical benefits from global market conditions, it needs to keep its costs down and continue expansion of new product lines to maintain a healthy growth rate.
Similar Companies
- BSX
- MDTC
- SYK
- ABT
Sources and Disclaimers
Data Sources:
- Merit Medical Systems Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
- Company Press Releases
Disclaimers:
This analysis is based on available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market conditions are constantly evolving, and future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Merit Medical Systems Inc
Exchange NASDAQ | Headquaters South Jordan, UT, United States | ||
IPO Launch date 1990-08-09 | Founder, CEO, President & Chairman Mr. Fred P. Lampropoulos | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 7400 | Website https://www.merit.com |
Full time employees 7400 | Website https://www.merit.com | ||
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures, as well as non-pharmacological treatment of gastroesophageal reflux disease. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.